-
-
-
-
-
-
-
Acadia Pharma (ACAD) Tops Q4 EPS by 146c ; Offers Guidance
-
-
-
-
-
-
-
Canaccord Genuity Reiterates Buy Rating on Acadia Pharmaceuticals (ACAD)
-
-
-
-
-
-
-
Acadia Pharmaceuticals (ACAD) PT Raised to $37 at H.C. Wainwright
-
-
-
-
-
-
-
Acadia Pharma (ACAD) Tops Q3 EPS by 28c, provides guidance
-
-
-
-
-
-
-
Acadia Pharmaceuticals (ACAD) PT Lowered to $21 at Oppenheimer
-
-
-
-
-
-
-
Wells Fargo on Soleno Therapeutics Inc. (SLNO): 'We Think Shares Should Trade Up at Least +20% on ACAD Failure'
-
-
-
-
-
-
-
ACADIA publishes real-world data on DAYBUE for Rett syndrome treatment
-
353,174 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

